<< Back to News

LONSURF® Receives New FDA Approval

On February 25, 2019 Taiho Oncology, Inc. announced that the United States Food and Drug Administration (FDA) has approved LONSURF® as a treatment for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.  

Click Here to read the entire press release.

https://www.taihooncology.com/us/newsroom/press-releases/2019-02-25-LON-PM-US-1213-FDA-Approves-Gastric